公开(公告)号：EP3594203A1

公开(公告)日：2020-01-15

申请号：EP18763726.9

申请日：2018-03-07

申请人： Takeda Pharmaceutical Company Limited

发明人： DAINI, Masaki ,  MIYANOHANA, Yuhei ,  MIKAMI, Satoshi ,  KAJITA, Yuichi ,  OGINO, Masaki ,  KOIKE, Tatsuki ,  TAKEUCHI, Kohei

IPC分类号： C07D207/12

摘要： The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):

wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：EP3342772A1

公开(公告)日：2018-07-04

申请号：EP16839293.4

申请日：2016-08-24

申请人： Takeda Pharmaceutical Company Limited

发明人： KAIEDA, Akira ,  ISHII, Naoki ,  NARA, Hiroshi ,  YOSHIKAWA, Masato ,  DAINI, Masaki

IPC分类号： C07D413/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/5377 ,  A61P1/04 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P43/00 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

CPC分类号： A61K31/454 ,  A61K31/4545 ,  A61K31/5377 ,  A61P29/00 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

摘要： The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of inflammatory disease and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I):

wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：EP3327019A1

公开(公告)日：2018-05-30

申请号：EP16827730.9

申请日：2016-07-15

申请人： Takeda Pharmaceutical Company Limited

发明人： KAIEDA, Akira ,  DAINI, Masaki ,  NARA, Hiroshi ,  YOSHIKAWA, Masato ,  ISHII, Naoki ,  TOYOFUKU, Masashi ,  HIDAKA, Kousuke

IPC分类号： C07D413/04 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444

CPC分类号： A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

摘要： The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I) :

wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：EP3129369A1

公开(公告)日：2017-02-15

申请号：EP15721046.9

申请日：2015-04-09

申请人： Takeda Pharmaceutical Company Limited

发明人： MATSUMOTO, Shigemitsu ,  HATTORI, Yasushi ,  TOYOFUKU, Masashi ,  MORIMOTO, Shinji ,  DAINI, Masaki ,  KOJIMA, Takuto ,  KAKU, Tomohiro ,  ITO, Mitsuhiro

IPC分类号： C07D413/14 ,  C07D213/82 ,  C07D231/14 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D417/12 ,  C07D417/14 ,  C07D285/08 ,  C07D285/135 ,  A61K31/421 ,  A61K31/166

CPC分类号： C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

摘要翻译： 本发明提供具有赖氨酸特异性脱甲基酶-1抑制作用的化合物，可用作精神分裂症，发育障碍，特别是具有智力障碍的疾病（例如自闭症谱系，Rett综合征， 唐氏综合症，歌舞伎综合征，脆弱X综合征，克莱斯特综合征，1型神经纤维瘤病，Noonan综合征，结节性硬化症），神经退行性疾病（如阿尔茨海默病，帕金森病，脊髓小脑变性（例如，牙周性苍白球萎缩症）和亨廷顿疾病）），癫痫 （例如，Dravet综合征）或药物依赖性等。 由下式表示的化合物，其中每个符号如本说明书中所定义，或其盐。

公开(公告)号：EP4153583A1

公开(公告)日：2023-03-29

申请号：EP21737768.8

申请日：2021-05-20

申请人： Takeda Pharmaceutical Company Limited

发明人： HASUI, Tomoaki ,  MIKAMI, Satoshi ,  YAMASHITA, Toru ,  NAKAMURA, Shinji ,  MORIMOTO, Shinji ,  IMAEDA, Toshihiro ,  TAKAMI, Kazuaki ,  DAINI, Masaki ,  KAKEI, Hiroyuki ,  NAKAMURA, Minoru ,  YAMAGUCHI, Fumie ,  WANG, Chunxiang ,  TAKASHIMA, Sachie ,  HASHIZUME, Shogo

IPC分类号： C07D403/06 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14 ,  C07D403/14 ,  A61K31/4178 ,  A61K31/4155 ,  A61K31/5377 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/351 ,  A61K31/454 ,  A61P25/00 ,  A61P25/04 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P25/36

公开(公告)号：EP4005638A1

公开(公告)日：2022-06-01

申请号：EP20846028.7

申请日：2020-07-28

申请人： Takeda Pharmaceutical Company Limited

发明人： TANAKA, Yuta ,  TANAKA, Yuta ,  KIKUCHI, Fumiaki ,  YAMAMOTO, Takeshi ,  NAKAMURA, Minoru ,  TAKAMI, Kazuaki ,  MURAKAMI, Masataka ,  DAINI, Masaki ,  WADA, Yasufumi ,  KAKEGAWA, Keiko ,  KASAHARA, Takahito ,  OHASHI, Tomohiro ,  WANG, Junsi ,  IKEDA, Zenichi ,  PÜNNER, Florian ,  SETO, Masaki ,  MIKAMI, Satoshi ,  SASAKI, Minoru

IPC分类号： A61P25/16 ,  A61P25/28 ,  A61P39/02 ,  A61P43/00 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D519/00 ,  A61K31/4162 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/551

摘要： The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I):

wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：EP2857400A1

公开(公告)日：2015-04-08

申请号：EP13797604.9

申请日：2013-05-31

申请人： Takeda Pharmaceutical Company Limited

发明人： NARA, Hiroshi ,  DAINI, Masaki ,  KAIEDA, Akira ,  KAMEI, Taku ,  IMAEDA, Toshihiro ,  KIKUCHI, Fumiaki

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/444 ,  A61K31/5377 ,  A61P1/04 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P29/00 ,  A61P37/00 ,  A61P43/00

CPC分类号： C07D471/04

摘要： The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof.
The present invention relates to a compound represented by the formula

wherein each symbol is as defined in the specification, or a salt thereof.

摘要翻译： 本发明提供具有优越的JAK抑制作用的化合物，其可用作预防或治疗自身免疫性疾病（类风湿性关节炎，牛皮癣，炎性肠病，舍格伦综合征，贝切特氏病，多发性硬化症，系统性红斑狼疮， （白血病，子宫平滑肌肉瘤，前列腺癌，多发性骨髓瘤，恶病质，骨髓纤维化等）等，或其盐。 本发明涉及由下式表示的化合物或其盐，其中每个符号如说明书中所定义。

公开(公告)号：EP4005637A1

公开(公告)日：2022-06-01

申请号：EP20845923.0

申请日：2020-07-28

申请人： Takeda Pharmaceutical Company Limited

发明人： TANAKA, Yuta ,  TANAKA, Yuta ,  KAKEGAWA, Keiko ,  KASAHARA, Takahito ,  KIKUCHI, Fumiaki ,  YAMAMOTO, Takeshi ,  OHASHI, Tomohiro ,  IKEDA, Zenichi ,  PÜNNER, Florian ,  NAKAMURA, Minoru ,  TAKAMI, Kazuaki ,  MURAKAMI, Masataka ,  DAINI, Masaki ,  SETO, Masaki ,  MIKAMI, Satoshi ,  SASAKI, Minoru

IPC分类号： A61P25/16 ,  A61P25/28 ,  A61P39/02 ,  A61P43/00 ,  C07D237/24 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D471/04 ,  C07D213/82 ,  C07D213/84 ,  C07D213/85 ,  C07D239/36 ,  A61K31/4412 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/497 ,  A61K31/50

摘要： The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I):

wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：EP3325475B1

公开(公告)日：2020-03-18

申请号：EP16760203.6

申请日：2016-07-15

申请人： Takeda Pharmaceutical Company Limited

发明人： KAIEDA, Akira ,  TOYOFUKU, Masashi ,  DAINI, Masaki ,  NARA, Hiroshi ,  YOSHIKAWA, Masato ,  ISHII, Naoki ,  HIDAKA, Kousuke

IPC分类号： C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04 ,  C07D491/107 ,  C07D498/08 ,  A61K31/4245 ,  A61P37/00

公开(公告)号：EP3325475A1

公开(公告)日：2018-05-30

申请号：EP16760203.6

申请日：2016-07-15

申请人： Takeda Pharmaceutical Company Limited

发明人： KAIEDA, Akira ,  TOYOFUKU, Masashi ,  DAINI, Masaki ,  NARA, Hiroshi ,  YOSHIKAWA, Masato ,  ISHII, Naoki ,  HIDAKA, Kousuke

IPC分类号： C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04 ,  C07D491/107 ,  C07D498/08 ,  A61K31/4245 ,  A61P37/00

摘要： wherein each symbol is as defined in the specification, or a salt thereof.